NO2017040I1 - Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC - Google Patents

Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Info

Publication number
NO2017040I1
NO2017040I1 NO2017040C NO2017040C NO2017040I1 NO 2017040 I1 NO2017040 I1 NO 2017040I1 NO 2017040 C NO2017040 C NO 2017040C NO 2017040 C NO2017040 C NO 2017040C NO 2017040 I1 NO2017040 I1 NO 2017040I1
Authority
NO
Norway
Prior art keywords
natalizumab
spc
prolonged
monoclonal antibody
humanized monoclonal
Prior art date
Application number
NO2017040C
Other languages
English (en)
Other versions
NO2017040I2 (no
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of NO2017040I1 publication Critical patent/NO2017040I1/no
Publication of NO2017040I2 publication Critical patent/NO2017040I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO2017040C 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC NO2017040I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (2)

Publication Number Publication Date
NO2017040I1 true NO2017040I1 (no) 2017-08-01
NO2017040I2 NO2017040I2 (no) 2018-08-28

Family

ID=22684288

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19963097A NO319867B1 (no) 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO19963097A NO319867B1 (no) 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody

Country Status (21)

Country Link
EP (2) EP1759709B1 (no)
JP (5) JP4115517B2 (no)
KR (1) KR100367948B1 (no)
CN (1) CN1211123C (no)
AT (1) ATE333895T1 (no)
AU (1) AU703152B2 (no)
CA (1) CA2182013C (no)
DE (2) DE69535133T2 (no)
DK (2) DK1759709T3 (no)
ES (2) ES2424292T3 (no)
FI (1) FI117509B (no)
FR (1) FR06C0024I2 (no)
HU (1) HU220799B1 (no)
LU (1) LU91271I2 (no)
MX (1) MX9602971A (no)
NL (1) NL300238I2 (no)
NO (3) NO319867B1 (no)
NZ (1) NZ279730A (no)
PL (1) PL181827B1 (no)
PT (1) PT804237E (no)
WO (1) WO1995019790A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
RS50086B (sr) * 1999-04-22 2009-01-22 Biogen Idec Ma Inc., Upotreba antagonista subjedinica alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200100651A (et) 1999-06-01 2003-02-17 Biogen, Inc. VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
ATE447969T1 (de) * 1999-12-16 2009-11-15 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CN1561345B (zh) 2001-04-13 2011-09-14 比奥根艾迪克Ma公司 抗vla-1的抗体
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
AU2004303696B2 (en) 2003-12-22 2011-03-31 Ea Pharma Co., Ltd. Novel phenylalanine derivative
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
JP5496658B2 (ja) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
TWI614028B (zh) * 2007-06-14 2018-02-11 百健Ｍａ公司 抗體調配物
CN101889036B (zh) 2007-12-13 2013-01-02 株式会社德山 光致变色固化性组合物
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
KR101346530B1 (ko) 2009-03-20 2013-12-31 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ES2805873T3 (es) 2010-04-16 2021-02-15 Biogen Ma Inc Anticuerpos anti-VLA-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ME02858B (me) 2011-05-02 2018-04-20 Millennium Pharm Inc Formulacija za anti- 4 7 antitelo
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN110997714A (zh) * 2017-02-17 2020-04-10 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
US20200199525A1 (en) 2017-06-08 2020-06-25 Polpharma Biologics S.A. Improved Methods of Cell Culture
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
NZ279730A (en) 1998-04-27
FI962958A (fi) 1996-09-24
EP0804237A1 (en) 1997-11-05
NO2017040I2 (no) 2018-08-28
FI117509B (fi) 2006-11-15
HUT75129A (en) 1997-04-28
EP0804237A4 (en) 2003-04-16
DK1759709T3 (da) 2013-06-10
NO2006008I1 (no) 2006-08-07
CA2182013A1 (en) 1995-07-27
KR970700513A (ko) 1997-02-12
EP0804237B1 (en) 2006-07-26
LU91271I2 (fr) 2006-10-02
DE69535133D1 (de) 2006-09-07
ES2424292T3 (es) 2013-09-30
KR100367948B1 (ko) 2003-07-12
AU703152B2 (en) 1999-03-18
PL315634A1 (en) 1996-11-25
NO2006008I2 (no) 2009-06-15
EP0804237B8 (en) 2006-11-08
FR06C0024I1 (no) 2006-10-13
FR06C0024I2 (fr) 2009-01-02
HU220799B1 (hu) 2002-05-28
JP4115517B2 (ja) 2008-07-09
JPH09508272A (ja) 1997-08-26
NL300238I1 (no) 2006-10-02
CN1140413A (zh) 1997-01-15
WO1995019790A1 (en) 1995-07-27
DE122006000043I1 (de) 2007-02-15
PT804237E (pt) 2006-10-31
NL300238I2 (nl) 2007-05-01
AU1696095A (en) 1995-08-08
CA2182013C (en) 2007-07-17
FI962958A0 (fi) 1996-07-24
EP1759709A1 (en) 2007-03-07
JP2013173738A (ja) 2013-09-05
ATE333895T1 (de) 2006-08-15
MX9602971A (es) 1998-01-31
JP2006045237A (ja) 2006-02-16
DK0804237T3 (da) 2006-10-16
CN1211123C (zh) 2005-07-20
NO319867B1 (no) 2005-09-26
HU9602019D0 (en) 1996-09-30
NO963097D0 (no) 1996-07-24
PL181827B1 (pl) 2001-09-28
JP2009235078A (ja) 2009-10-15
NO963097L (no) 1996-09-24
EP1759709B1 (en) 2013-02-27
JP5487382B2 (ja) 2014-05-07
ES2270425T3 (es) 2007-04-01
JP2013165718A (ja) 2013-08-29
DE69535133T2 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
NO2017040I1 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
ATE449791T1 (de) Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
DE69429095D1 (de) Humanisierte antikoerper
DK0724456T3 (da) CD40-Antistoffer
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DE60039354D1 (de) Verfahren zur Stabilisierung von chimären Immunoglobulinen oder Immunoglobulinfragmenten und stabilisiertes Anti-EGP-2-scFv-Fragment
NO20010747L (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
FI20040696A (fi) Immunoglobuliini-isotyyppiä vastaan suunnatut uudelleenmuotoillut monoklonaaliset vasta-aineet
DK0585570T3 (da) Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse